|
Wednesday, 15 July 2020, 14:21 HKT/SGT | |
| |
|
|
|
Empowers its European Staff to Capture Advanced Medical Knowledge, Promotes Innovation in Technology, and Enhances the Quality and Service Standard of the Refractive Field |
HONG KONG, July 15, 2020 - (ACN Newswire) - EuroEyes International Eye Clinic Limited ("EuroEyes" or the "Company", stock code: 1846), a well-established leading ophthalmic medical group, is pleased to announce that Dr. Burkhard Dick ("Dr. Dick") has joined The EuroEyes International Medical Advisory Board. In the future. He will strive to promote continued medical education for European staff of the Group, foster innovation in technology and raise the quality and service standard of the refractive field.
 | Dr. Burkhard Dick |
As one of the most influential surgeons who pioneered bladeless laser cataract surgery in Europe, Dr. Dick has a renowned reputation in the global ophthalmology community, serving as a regular lecturer at international meetings, such as the European Society of Cataract & Refractive Surgeons, the Deutsche Ophthalmologische Gesellschaft, the Deutschen Ophthalmochirurgen (DOC), the Deutschsprachige Gesellschaft fur Intraokularlinsen-Implanation und Refraktive Chirurgie, and the American Society of Cataract and Refractive Surgery. He has instructed fellows from 38 different countries in state-of-the-art cataract, refractive, glaucoma, and vitreoretinal surgery. In the "Power List 2018" ranking of the world's most influential ophthalmologists by the publication, The Ophthalmologist, Dr. Dick was listed among the Top 20, and he has been in the Top 50 several times before.
As the most influential ophthalmologist in the world, Dr. Dick joined the eye hospital of the University of Mainz in 1996 where he became a professor in 2003. In 2006, Dr. Dick was appointed as the chair of the department of ophthalmology at the University of Bochum and director of the University Eye Clinic, conducting R&D and promoting the cataract and refractive treatment, and leading the team to establish an internationally renowned ophthalmology clinic with outstanding achievements.
During his 30 years of practice, Dr. Dick persistently pursued more advanced and effective surgical techniques to promote the development of ophthalmology medical education.
Dr. Jorn Slot Jorgensen, executive director, chairman of the board of directors, and chief executive officer of EuroEyes, said: "We are excited that Dr. Burkhard Dick joins the EuroEyes international medical advisory board. EuroEyes plans to introduce more advanced vision correction technologies and equipment in the future. Leveraging Dr. Dick's, one of the pioneers in the industry, excellent and rich experience in surgery and R&D, we are confident to enhance the Group's comprehensive strength, promote technological innovation, and improve medical quality and service standards, as well as provide European and Chinese customers with the world's leading vision correction surgery, brings the best returns to our shareholders and investors."
Topic: Press release summary
Sectors: Daily Finance, Healthcare & Pharm, Funds & Equities
https://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
Latest Press Releases
Olympus Appoints New CEO
Friday, April 25, 2025 9:43:00 PM
|
|
|
Strengthening Hong Kong-Zhejiang ties
Apr 25, 2025 21:05 HKT/SGT
|
|
|
Graphene Manufacturing Group Provides Quarterly ATM Sales Update
Apr 25, 2025 20:29 HKT/SGT
|
|
|
Edvantage Group Announces FY2025 Interim Results
Apr 25, 2025 20:05 HKT/SGT
|
|
|
TIME Interconnect Technology Limited Announces Final Results For The Year Ended 31 December 2024
Apr 25, 2025 20:03 HKT/SGT
|
|
|
NEC achieves Japan's longest terrestrial wireless optical communication over 10 km
Friday, April 25, 2025 4:50:00 PM
|
|
|
Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia
Apr 25, 2025 15:49 HKT/SGT
|
|
|
DENSO Announces Year-End Financial Results
Friday, April 25, 2025 11:17:00 AM
|
|
|
Mooreast Holdings Announces Business Update
Apr 25, 2025 10:00 HKT/SGT
|
|
|
HighTide Therapeutics to Showcase New Analyses of Phase 2 MASH/T2DM Studies of Berberine Ursodeoxycholate (HTD1801) and Pre-Clinical Results of Rimtoregtide (HTD4010) in Presentations at EASL Congress 2025
Apr 24, 2025 18:43 HKT/SGT
|
|
|
|
More Press release >> |
|
|
|